Cargando…
Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer
BACKGROUND: Secondary cytoreductive surgery (SCS) is possible in selected patients with recurrent epithelial ovarian cancer (EOC). The goal of SCS is complete resection, although chemotherapy is always followed. Delayed intervals between primary debulking surgery and adjuvant chemotherapy was report...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937657/ https://www.ncbi.nlm.nih.gov/pubmed/31892329 http://dx.doi.org/10.1186/s13048-019-0602-5 |
_version_ | 1783483906892234752 |
---|---|
author | Jeong, Soo Young Choi, Chel Hun Kim, Tae Joong Lee, Jeong Won Kim, Byoung-Gie Bae, Duk Soo Lee, Yoo-Young |
author_facet | Jeong, Soo Young Choi, Chel Hun Kim, Tae Joong Lee, Jeong Won Kim, Byoung-Gie Bae, Duk Soo Lee, Yoo-Young |
author_sort | Jeong, Soo Young |
collection | PubMed |
description | BACKGROUND: Secondary cytoreductive surgery (SCS) is possible in selected patients with recurrent epithelial ovarian cancer (EOC). The goal of SCS is complete resection, although chemotherapy is always followed. Delayed intervals between primary debulking surgery and adjuvant chemotherapy was reported to be associated with poorer survivals, however, the role of intervals in recurrent disease is still unknown. MATERIALS AND METHODS: This retrospective cohort study reviewed data from electronic medical records of women with recurrent EOC treated at Samsung Medical Centre, Seoul, Korea, between January 1, 2002, and December 31, 2015. Patients who underwent SCS with adjuvant chemotherapy for recurrent EOC were eligible. We defined intervals as the period between the day of SCS and the first cycle of adjuvant chemotherapy. RESULTS: Seventy-nine patients were eligible for this study. Their median age was 48 (range, 18–69) years and median interval between the date of SCS and initiation of adjuvant chemotherapy was 10 (range, 4–115) days. The rate of complete resection was 72.2% (57/79). Division of the patients by interval (Group 1, interval ≤ 10 days; Group 2, interval > 10 days) revealed no difference in clinical parameters. No gross residual disease after SCS (no vs. any gross residual, p = 0.002) and longer platinum-free survival (over 12 vs. 6–12 months, p = 0.023) were independent favorable prognostic factors in Cox model; however, the intervals did not affect survival. CONCLUSIONS: Delayed intervals to adjuvant chemotherapy after secondary cytoreductive surgery is not associated with decreased survivals. It is important to identify recurrent EOC patients who might have no gross residual disease following SCS. Moreover, surgeons should strive for complete resection. |
format | Online Article Text |
id | pubmed-6937657 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-69376572019-12-31 Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer Jeong, Soo Young Choi, Chel Hun Kim, Tae Joong Lee, Jeong Won Kim, Byoung-Gie Bae, Duk Soo Lee, Yoo-Young J Ovarian Res Research BACKGROUND: Secondary cytoreductive surgery (SCS) is possible in selected patients with recurrent epithelial ovarian cancer (EOC). The goal of SCS is complete resection, although chemotherapy is always followed. Delayed intervals between primary debulking surgery and adjuvant chemotherapy was reported to be associated with poorer survivals, however, the role of intervals in recurrent disease is still unknown. MATERIALS AND METHODS: This retrospective cohort study reviewed data from electronic medical records of women with recurrent EOC treated at Samsung Medical Centre, Seoul, Korea, between January 1, 2002, and December 31, 2015. Patients who underwent SCS with adjuvant chemotherapy for recurrent EOC were eligible. We defined intervals as the period between the day of SCS and the first cycle of adjuvant chemotherapy. RESULTS: Seventy-nine patients were eligible for this study. Their median age was 48 (range, 18–69) years and median interval between the date of SCS and initiation of adjuvant chemotherapy was 10 (range, 4–115) days. The rate of complete resection was 72.2% (57/79). Division of the patients by interval (Group 1, interval ≤ 10 days; Group 2, interval > 10 days) revealed no difference in clinical parameters. No gross residual disease after SCS (no vs. any gross residual, p = 0.002) and longer platinum-free survival (over 12 vs. 6–12 months, p = 0.023) were independent favorable prognostic factors in Cox model; however, the intervals did not affect survival. CONCLUSIONS: Delayed intervals to adjuvant chemotherapy after secondary cytoreductive surgery is not associated with decreased survivals. It is important to identify recurrent EOC patients who might have no gross residual disease following SCS. Moreover, surgeons should strive for complete resection. BioMed Central 2019-12-31 /pmc/articles/PMC6937657/ /pubmed/31892329 http://dx.doi.org/10.1186/s13048-019-0602-5 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Jeong, Soo Young Choi, Chel Hun Kim, Tae Joong Lee, Jeong Won Kim, Byoung-Gie Bae, Duk Soo Lee, Yoo-Young Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer |
title | Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer |
title_full | Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer |
title_fullStr | Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer |
title_full_unstemmed | Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer |
title_short | Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer |
title_sort | interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937657/ https://www.ncbi.nlm.nih.gov/pubmed/31892329 http://dx.doi.org/10.1186/s13048-019-0602-5 |
work_keys_str_mv | AT jeongsooyoung intervalbetweensecondarycytoreductivesurgeryandadjuvantchemotherapyisnotassociatedwithsurvivalsinpatientswithrecurrentovariancancer AT choichelhun intervalbetweensecondarycytoreductivesurgeryandadjuvantchemotherapyisnotassociatedwithsurvivalsinpatientswithrecurrentovariancancer AT kimtaejoong intervalbetweensecondarycytoreductivesurgeryandadjuvantchemotherapyisnotassociatedwithsurvivalsinpatientswithrecurrentovariancancer AT leejeongwon intervalbetweensecondarycytoreductivesurgeryandadjuvantchemotherapyisnotassociatedwithsurvivalsinpatientswithrecurrentovariancancer AT kimbyounggie intervalbetweensecondarycytoreductivesurgeryandadjuvantchemotherapyisnotassociatedwithsurvivalsinpatientswithrecurrentovariancancer AT baeduksoo intervalbetweensecondarycytoreductivesurgeryandadjuvantchemotherapyisnotassociatedwithsurvivalsinpatientswithrecurrentovariancancer AT leeyooyoung intervalbetweensecondarycytoreductivesurgeryandadjuvantchemotherapyisnotassociatedwithsurvivalsinpatientswithrecurrentovariancancer |